Black Hawk Acquisition Shareholders Approve Its Proposed Business Combination With Vesicor Therapeutics

On October 13, 2026, Black Hawk Acquisition Corporation (the "Company") held an extraordinary general meeting of Shareholders (the "Extraordinary General Meeting"). The record date for shareholders entitled to notice of and to vote at the Extraordinary General Meeting was September 1, 2026. As of the record date, 4,153,577 ordinary shares were issued and outstanding and entitled to vote at the Extraordinary General Meeting. Of these shares, 3,211,516 shares, representing approximately 77.3% of the outstanding ordinary shares entitled to vote, were present by virtually or represented by proxy at the Extraordinary General Meeting, constituting a quorum.

At the Extraordinary General Meeting, shareholders voted on eight proposals, each of which is described in greater detail in the Company’s definitive proxy statement. The final voting results for each proposal are set forth below:

Proposal 1 – Business Combination Proposal

The Company’s shareholders approved, by ordinary resolution, the Business Combination Agreement, dated as of April 26, 2025 (as amended or supplemented from time to time, the "Business Combination Agreement"), by and among the Company, Vesicor Therapeutics, Inc. ("Vesicor") and BH Merger Sub, Inc., and the transactions contemplated thereby (the "Business Combination Proposal").